20 Eastbourne Terrace
About LivaNova PLCLivaNova PLC, headquartered in London, UK, is a global medical technology company formed by the merger of Sorin S.p.A, a leader in the treatment of cardiovascular diseases, and Cyberonics Inc., a medical device company with core expertise in neuromodulation. LivaNova transforms medical innovation into meaningful solutions for the benefit of patients, healthcare professionals and healthcare systems. The company employs approximately 4,600 employees worldwide. With a presence in more than 100 countries, LivaNova operates as three business franchises: Cardiac Rhythm Management, Cardiac Surgery and Neuromodulation, with operating headquarters in Clamart (France), Mirandola (Italy) and Houston (U.S.A.), respectively.
CEO: Damien McDonald
CFO: Vivid Sehgal
Please click here for LivaNova job opportunities.
117 articles with LivaNova PLC
LivaNova VNS Therapy System for Drug-Resistant Epilepsy Could Save $77,000 Per Patient Over Five Years
Analysis finds overall cost savings far exceed system-related costs
LivaNova Launches Global Clinical Registry to Assess VNS Therapy Treatment for Drug-Resistant Epilepsy Patients
LivaNova PLC today announced the first implanted patient and official launch of a global registry to evaluate the use of LivaNova’s Vagus Nerve Stimulation Therapy® (VNS Therapy) System for patients with drug-resistant epilepsy
Company now focused on INTERLUDE CE Mark trial, building upon positive patient outcomes
LivaNova PLC reported results for the quarter ended June 30, 2018.
LivaNova PLC will host a conference call to discuss its second quarter 2018 results on Wednesday, Aug. 1, 2018 at 1 p.m. London time (8 a.m. Eastern Daylight Time).
LivaNova Receives FDA Clearance and Completes First Implant for its MEMO 4D Semi-rigid Mitral Annuloplasty Ring
MEMO 4D now offers a broader range of ring sizes from 24 to 42mm allowing an additional patient population with mitral regurgitation (“MR”) to be treated
Elected by the Company’s shareholders to its board of directors during its June 12 annual general meeting.
LivaNova PLC today announced that Japan’s Ministry of Health, Labour and Welfare has approved the Company’s Perceval® sutureless aortic heart valve to treat aortic valve disease.
LivaNova PLC announced company executives will present at two upcoming healthcare conferences.
LivaNova Comments on the U.S. Centers for Medicare & Medicaid Services’ Reconsideration of its National Coverage Determination for VNS Therapy for Treatment-Resistant Depression
LivaNova PLC issued a statement in regard to the U.S. Centers for Medicare & Medicaid Services’ (“CMS”) publication.
LivaNova PLC reported results for the quarter ended March 31, 2018.
LivaNova PLC announced it has successfully completed the divestiture of its Cardiac Rhythm Management (“CRM”) business to MicroPort Scientific Corporation (HK: 00853) (“MicroPort”) for $190 million in cash.
LivaNova PLC announced its Inspire® innovative adult oxygenator system has treated its one-millionth patient.
LivaNova PLC has announced the first patient enrollment in the Perceval® Valve Clinical study for Chinese Registration (“PERFECT”) Trial.
LivaNova Enters into Definitive Agreement to Divest Its Cardiac Rhythm Management Business Franchise to MicroPort Scientific Corporation
LivaNova PLC announced that it has entered into a definitive Stock and Asset Purchase Agreement to divest its Cardiac Rhythm Management business franchise to MicroPort Scientific Corporation.
For the fourth quarter of 2017, worldwide sales from continuing operations were $278.4 million, an increase of 11.5 percent on a reported basis and an increase of 8.1 percent on a constant currency basis, as compared to the same quarter of the previous year.
Company will add advanced cardiopulmonary temporary support solutions to its portfolio.
The phthalate (DEHP)-free flexible tubing features exceptional transparency and a wire-reinforcement spring to deliver flexibility without kinking.
LivaNova will host a conference call to discuss its fourth quarter and full-year 2017 results on Wednesday, Feb. 28, 2018 at 8 a.m. CST (2 p.m. GMT).
This study is a post-market, prospective, interventional, multi-center trial designed to report the overall incidence of reduced leaflet motion identified by CT imaging in patients receiving a commercially approved LivaNova bioprosthetic aortic heart valve.